Client Stories

Veryst’s clients include some of the most innovative companies in the world, working on some of the most exciting and cutting-edge products. Our team of subject matter experts has provided actionable guidance to accelerate product development for Fortune 20 companies, one-person start-ups, and everything in between. We base our advice on our unrivaled technical depth in testing, failure analysis, materials science, modeling, and simulation of nonlinear, coupled problems. We work every day to serve our clients so that they can deliver the best products to their customers.



3D BioLabs and Veryst

3D BioLabs and Veryst: Advancing Implantable Tissue Devices

3D BioLabs partnered with Veryst to advance bioengineered organ technology using fluid mechanics, structural mechanics, materials science, and multiphysics simulation. Together, we developed 3D-printed liver devices featuring optimized, fractal-like vascular networks that mimic physiological blood flow, accelerating R&D timelines and yielding peer-reviewed publications and patents aimed at solving the organ transplant shortage.
Predicted stresses within smart pill.

Biora Therapeutics and Veryst: Breakthrough Smart Pill Development

Biora Therapeutics’ BioJet™ oral delivery platform delivers large-molecule drugs to the gut using needle-free, liquid jet injection. Biora™ partnered with Veryst to use our expertise in fluid mechanics, structural mechanics, and materials science—combined with advanced simulation—to optimize device activation and jetting, accelerating development and reducing risk. The result: robust, preclinical-ready devices developed on an accelerated timeframe.
Merck AIDC Teaser

Merck and Veryst Collaborate on Dual Chamber Autoinjector Modeling

In a recent collaboration, Veryst and Merck reveal how physics-based modeling enables rapid, virtual optimization of dual-chamber autoinjectors. Our predictive framework estimates injection time, stopper trajectories, and diluent volume for various device and formulation parameters—allowing biopharma scientists and formulators to quickly estimate drug-device compatibility, accelerating drug & injection device co-development.

Can we help? Just want to keep in touch?